The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
more than 20% rise today - someone knows something. News tomorrow?
...someone is sniffing around us at last.
That's the difference, this WASN'T a Covid test kit company, it only started getting in to test kits late last year and in fact in the rns it states "Revenue from this product portfolio has helped IDS deliver the strong performance seen in H2 FY21" so they are indeed making money from their Covid testing portfolio.
I disagree with all of you, this was above 260p during the main 'pandemic' and they have failed to capitalise on it
most covid companies did well like avacta, genedrive, novacyte
this covid test kit company bloody went DOWN during this mess
This share is a medium to long term hold and always has been, I like it because it's stable with good steady growth even during the pandemic, I agree with the previous post in that at some point IDH will probably be taken over.
Draft, That puts them in the same grouping as the majority of the diagnostics companies doesn’t it? You are quoting pretty much the 1 off exception of Novacyte (whose star has been rapidly falling in recent weeks)......
Whilst the covid story is far from over towards offering future business opportunities to IDH as mentioned in their RNS, there is plenty to like about these improved results in the last 6 months and the future growth potential. Also nice to see a cash holding sat at nearly 1/2 their mcap and so there is no chance of a placing around the corner.
I actually see IDH as a potential takeover target down the line for their IP etc, as the fallout from covid will surely be to put a new level of importance and focus on diagnostics in the eyes of the big pharmaceutical companies.
they have failed to capitalise on covid test kits when people like novacyte have made hundreds of millions from them
awful update.
Nice steady growth but the important bit in the rns is..
"IDS now has a comprehensive portfolio of COVID-19 tests available - ranging across fully automated IgG and IgM antibody tests, manual ELISA tests and distribution rights for a variety of rapid antibody and antigen tests. Revenue from this product portfolio has helped IDS deliver the strong performance seen in H2 FY21.
As explained in our most recent Interim Report, the focus of health authorities is currently on antigen testing - to test for an active infection of SARS CoV-2. IDS is working with our partners to gain approval for more convenient antigen tests, which are not reliant on the unpleasant nasopharyngeal swab sample collection method, to the European market. We will be well positioned to secure a share of this market assuming approval of these products is forthcoming.
In terms of antibody testing, with the progression of the vaccine rollouts globally, public health studies into antibody levels in the population should increase to enable the success of this program to be measured. This is likely to drive additional demand for antibody testing, and because a fully automated solution such as that offered by IDS provides better accuracy than rapid tests, and better laboratory efficiency than manual ELISA based tests, IDS is well positioned to win a share of the laboratory business for these tests."
Could have been worse, but not going to set the SP on fire! At least they still have plenty of cash in the bank and, ironically, it could be a blessing in disguise that their business is not dependant on Covid going forward!
this has done the worst out of the covid test kit companies, most others have had decent spikes
Yep normally middle of April, if the numbers are good then a short term spike to about 300p before inevitably falling back. One thing this company must improve on is a more regular news flow such as sales etc.
.... about 10 days.
theres still no proper trading update with numbers
we need real numbers, how many tests have these guys even sold so far?
So much potential here...
If each machine can do 10,000 (accurate, automated) tests per month, that's 300 per day, or maybe one/two aircraft's worth. If/when we can all start flying again, that could be one machine per flight..... or 100 machines per cruise departure?????!!
Anyway, just hoping I can get back into profit and at least the spread has narrowed.
The main points:
The Test has received the US Food and Drug Administration's ("FDA") Emergency Use Authorisation ("EUA"). As a result, IDS is now able to sell the Test to laboratories in the USA for clinical testing purposes.
The Test has been developed for identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection. The Test exceeds the FDA`s sensitivity and specificity requirements for laboratory run serology tests. It provides 100% Positive Percent Agreement after 7 days of diagnosis by RT-PCR and 99.6% Negative Percent Agreement for pre-endemic samples.
The Test does not cross react with other strains of coronavirus, significantly reducing the risk of false positives.
All steps of the Test are automated with no manual reagent preparation required, ensuring a high daily throughput. Test results are available within 25 minutes and can be run on any of the IDS-iSYS analysers which are already installed in numerous hospitals and laboratories in the USA. Each iSYS is capable of running over 10,000 tests per month.
Tests will be available for sale at the end of April. By providing our customers with this fully automated and flexible laboratory solution, IDS has the potential to increase our testing volumes in the US market, as well as attract new customers to the IDS platform.
All sales figures including Covid tests will be in the update released in two weeks time, that's when the sp should rise significantly.
READ IT CAREFULLY!!!
It does talk about sales of Covid 19 tests to date, without telling us how big they have been. At this SP, there is a lot of scope for upside surprise and not much downside.
This is the IDS-iSYS analyzer automated test I've been waited for, they should have done it months ago but at least they have it now. What this means is that they will hopefully now sell a load more of their really expensive automated testing machines, surprised really at the low Mcap still, it will re-rate at some point.
Definitely below the radar this one.
any other covid test company we would be up 100%!
No one interested in the RNS?
Not long now.
radio silence from IDH.
a trading update is needed really.
test they make for Technogenetics to the site, i just reckon we have not sold much and now we have surplus stock of the tests possibly